Higher fractionated doses inhibited the anti-tumor immune effect by up-regulating TREX1 and decreasing IFN-β expression, which could serve as a prognostic marker and potential target of immunotherapy in patients with lung adenocarcinoma. This evidence concerns the gene IFNB1 and lung adenocarcinoma.